Results 241 to 250 of about 152,178 (350)

Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab [PDF]

, 2017
John T. Butterfield, Hidong Kim, Daniel J. Knauer, Wendy K. Nevala, Svetomir N. Markovic   +4 more
openalex   +1 more source

Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloads. [PDF]

Med
Nikanjam M, Kurzrock R.
europepmc   +1 more source

Evidence-Based Consensus on the Diagnosis and Treatment of Advanced HER2-Positive and HER2-Low Breast Cancer in Colombia. [PDF]

J Clin Med
Lema M, Sua LF, Hernández Blanquisett AJ, Mantilla W, Pierre ME, Carranza H, Zuluaga Peña JR, Gutiérrez Raba AV, Franco SX.   +8 more
europepmc   +1 more source

0153 Routine clinical usage of trastuzumab (Herceptin®) in the adjuvant treatment of breast cancer in Germany - a prospective registry study

, 2009
Peter Dall, Martine Klausmann, F Khandan, Hubert Urbańczyk, Winfried Schoenegg, Jochen Eggert, A. Prechtl, Axel Hinke, Christian Lerchenmüller   +8 more
openalex   +1 more source

The ROOT-CTRCD study: exploring the relationship of oral health to cancer therapy-related cardiac dysfunction in HER2-positive breast cancer patients. [PDF]

Cardiooncology
Basuoni A, Al-Baimani K, AlKindi F, Dawelbeit W, AlHarrasi R, Al-Sharqi H, AlKindi N, Kamel AHM.   +7 more
europepmc   +1 more source

Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspective. [PDF]

Front Pharmacol
Zeng Z, Zhong L, Zhu L, Liao L, Zhu Z, Cao Y, Zheng D, Huang G, Chen W, Zhang L.   +9 more
europepmc   +1 more source

DESENSITIZATION TO PERTUZUMAB/TRASTUZUMAB/HYALURONIDASE-ZZXF IN A PATIENT WITH HYMENOPTERA ANAPHYLAXIS [PDF]

V. Saldana-Fraire, Laura Merino León, R. Estrada-Mendizabal, A. Gonzalez-Estrada, A. Canel Paredes   +4 more
openalex   +1 more source

Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. [PDF]

Breast Cancer (Dove Med Press)
Chen X, Lan X, Xiao L, Song L, Huang J, Xie X, Chen L, Bai X, Du C.   +8 more
europepmc   +1 more source

Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. [PDF]

Clin Cancer Res
Adesoye T, Dumbrava EE, Raghav KPS, Sahin AA, Chen H, Lee SS, Javle MM, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F.   +12 more
europepmc   +1 more source

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources